240 related articles for article (PubMed ID: 25110927)
1. Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions.
Palmateer NE; Taylor A; Goldberg DJ; Munro A; Aitken C; Shepherd SJ; McAllister G; Gunson R; Hutchinson SJ
PLoS One; 2014; 9(8):e104515. PubMed ID: 25110927
[TBL] [Abstract][Full Text] [Related]
2. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
[TBL] [Abstract][Full Text] [Related]
3. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland.
Allen EJ; Palmateer NE; Hutchinson SJ; Cameron S; Goldberg DJ; Taylor A
Int J Drug Policy; 2012 Sep; 23(5):346-52. PubMed ID: 22940142
[TBL] [Abstract][Full Text] [Related]
4. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.
Turner KM; Hutchinson S; Vickerman P; Hope V; Craine N; Palmateer N; May M; Taylor A; De Angelis D; Cameron S; Parry J; Lyons M; Goldberg D; Allen E; Hickman M
Addiction; 2011 Nov; 106(11):1978-88. PubMed ID: 21615585
[TBL] [Abstract][Full Text] [Related]
5. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.
Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012021. PubMed ID: 28922449
[TBL] [Abstract][Full Text] [Related]
6. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review.
Larney S; Peacock A; Leung J; Colledge S; Hickman M; Vickerman P; Grebely J; Dumchev KV; Griffiths P; Hines L; Cunningham EB; Mattick RP; Lynskey M; Marsden J; Strang J; Degenhardt L
Lancet Glob Health; 2017 Dec; 5(12):e1208-e1220. PubMed ID: 29074410
[TBL] [Abstract][Full Text] [Related]
7. Association between harm reduction intervention uptake and skin and soft tissue infections among people who inject drugs.
Dunleavy K; Munro A; Roy K; Hutchinson S; Palmateer N; Knox T; Goldberg D; Taylor A
Drug Alcohol Depend; 2017 May; 174():91-97. PubMed ID: 28319754
[TBL] [Abstract][Full Text] [Related]
8. HIV and hepatitis C prevalence, and related risk behaviours among people who inject drugs in three cities in Croatia: Findings from respondent-driven sampling surveys.
Handanagic S; Bozicevic I; Civljak M; Dominkovic Z; Sevic S; Barbaric J; Nemeth Blazic T; Dakovic Rode O; Begovac J
Int J Drug Policy; 2016 Jun; 32():57-63. PubMed ID: 27160504
[TBL] [Abstract][Full Text] [Related]
9. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis.
Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M
Addiction; 2018 Mar; 113(3):545-563. PubMed ID: 28891267
[TBL] [Abstract][Full Text] [Related]
10. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness.
MacArthur GJ; van Velzen E; Palmateer N; Kimber J; Pharris A; Hope V; Taylor A; Roy K; Aspinall E; Goldberg D; Rhodes T; Hedrich D; Salminen M; Hickman M; Hutchinson SJ
Int J Drug Policy; 2014 Jan; 25(1):34-52. PubMed ID: 23973009
[TBL] [Abstract][Full Text] [Related]
11. Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?
Grebely J; Dore GJ; Morin S; Rockstroh JK; Klein MB
J Int AIDS Soc; 2017 Jul; 20(1):22146. PubMed ID: 28782335
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of HIV and other drug-related harms associated with injecting in public places: national bio-behavioural survey of people who inject drugs.
Trayner KMA; McAuley A; Palmateer NE; Goldberg DJ; Shepherd SJ; Gunson RN; Tweed EJ; Priyadarshi S; Milosevic C; Hutchinson SJ
Int J Drug Policy; 2020 Mar; 77():102663. PubMed ID: 31981949
[TBL] [Abstract][Full Text] [Related]
13. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.
Martin NK; Hickman M; Hutchinson SJ; Goldberg DJ; Vickerman P
Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S39-45. PubMed ID: 23884064
[TBL] [Abstract][Full Text] [Related]
14. Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky.
Stone J; Fraser H; Young AM; Havens JR; Vickerman P
Int J Drug Policy; 2021 Feb; 88():102707. PubMed ID: 32151496
[TBL] [Abstract][Full Text] [Related]
15. Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data.
Palmateer N; Hutchinson S; McAllister G; Munro A; Cameron S; Goldberg D; Taylor A
J Viral Hepat; 2014 Jan; 21(1):25-32. PubMed ID: 24329854
[TBL] [Abstract][Full Text] [Related]
16. Low incidence of hepatitis C virus among prisoners in Scotland.
Taylor A; Munro A; Allen E; Dunleavy K; Cameron S; Miller L; Hickman M
Addiction; 2013 Jul; 108(7):1296-304. PubMed ID: 23297816
[TBL] [Abstract][Full Text] [Related]
17. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.
Stone J; Martin NK; Hickman M; Hutchinson SJ; Aspinall E; Taylor A; Munro A; Dunleavy K; Peters E; Bramley P; Hayes PC; Goldberg DJ; Vickerman P
Addiction; 2017 Jul; 112(7):1302-1314. PubMed ID: 28257600
[TBL] [Abstract][Full Text] [Related]
18. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14).
Wenz B; Nielsen S; Gassowski M; Santos-Hövener C; Cai W; Ross RS; Bock CT; Ratsch BA; Kücherer C; Bannert N; Bremer V; Hamouda O; Marcus U; Zimmermann R;
BMC Public Health; 2016 Sep; 16(1):927. PubMed ID: 27595567
[TBL] [Abstract][Full Text] [Related]
19. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
Fraser H; Martin NK; Brummer-Korvenkontio H; Carrieri P; Dalgard O; Dillon J; Goldberg D; Hutchinson S; Jauffret-Roustide M; Kåberg M; Matser AA; Matičič M; Midgard H; Mravcik V; Øvrehus A; Prins M; Reimer J; Robaeys G; Schulte B; van Santen DK; Zimmermann R; Vickerman P; Hickman M
J Hepatol; 2018 Mar; 68(3):402-411. PubMed ID: 29080808
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and risk factors associated with HIV/hepatitis B and HIV/hepatitis C co-infections among people who inject drugs in Mozambique.
Semá Baltazar C; Boothe M; Kellogg T; Ricardo P; Sathane I; Fazito E; Raymond HF; Temmerman M; Luchters S
BMC Public Health; 2020 Jun; 20(1):851. PubMed ID: 32493347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]